Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue
Ludimila Cavalcante, David P Kelsen, Kenneth H Yu1
1Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, 646-888-4188. YuK1@mskcc.org.
Abstract:
Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers

